What is Freespira?
Freespira operates at the intersection of medical device innovation and behavioral health. Its core offering is an FDA-cleared, four-week treatment program designed to address the physiological roots of panic attacks. By utilizing real-time biofeedback to stabilize respiration rates and exhaled carbon dioxide levels, the platform provides a tangible, measurable alternative to traditional therapy and medication. This approach addresses the life-altering avoidance behaviors associated with panic disorder, positioning the company as a critical player in the digital health ecosystem. The firm's business model relies on clinical efficacy and provider-supervised delivery, which enhances its credibility within the highly regulated healthcare market.
How much funding has Freespira raised?
Freespira has raised a total of $10M across 1 funding round:
Unspecified
$10M
Unspecified (2020): $10M with participation from Lightspeed Venture Partners, Medvest Capital, and Aphelion Capital LLC
Key Investors in Freespira
Lightspeed Venture Partners
A global multistage venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software, consumer, fintech, and infrastructure.
Medvest Capital
A venture capital firm established in 2013 that specializes in investing in early-stage medical device companies to improve patient outcomes and decrease delivery costs.
Aphelion Capital LLC
An investment firm participating in the funding round, providing strategic capital to support the growth of innovative healthcare solutions.
What's next for Freespira?
With this major strategic investment, Freespira is poised to accelerate its commercialization efforts and deepen its integration into existing healthcare delivery networks. The company's roadmap likely includes scaling its provider-supervised platform to reach a broader demographic of patients, potentially exploring partnerships with large-scale health systems and insurance providers to facilitate wider adoption. As the digital therapeutics market matures, Freespira's focus on clinical outcomes and non-invasive treatment protocols will be essential for maintaining its competitive advantage. Future growth will likely hinge on the company's ability to demonstrate long-term cost savings for payers while maintaining the high patient satisfaction rates that have characterized its early-stage development.
See full Freespira company page
